Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK NYSEAMERICAN:OGEN NASDAQ:PLXP NASDAQ:QLGN NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$4.46-1.3%$5.11$1.94▼$12.32$6.95M-0.130,124 shs46,077 shsOGENOragenics$1.26-3.1%$1.21$1.01▼$18.90$5.20M0.83243,528 shs65,516 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsQLGNQualigen Therapeutics$3.64-2.4%$3.05$1.61▼$10.45$6.17M0.324.67 million shs64,211 shsSLSSELLAS Life Sciences Group$2.14-0.9%$1.80$0.77▼$2.29$267.67M2.623.14 million shs4.81 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%-2.83%-12.20%-2.19%-13.23%OGENOragenics0.00%-3.08%+4.13%-6.67%-87.52%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%QLGNQualigen Therapeutics0.00%-12.50%+28.17%+20.93%-54.81%SLSSELLAS Life Sciences Group0.00%+12.04%+32.92%+20.90%+71.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$4.46-1.3%$5.11$1.94▼$12.32$6.95M-0.130,124 shs46,077 shsOGENOragenics$1.26-3.1%$1.21$1.01▼$18.90$5.20M0.83243,528 shs65,516 shsPLXPPLx Pharma$0.00$0.02▼$0.04$603K3.7912.96 million shs3,000 shsQLGNQualigen Therapeutics$3.64-2.4%$3.05$1.61▼$10.45$6.17M0.324.67 million shs64,211 shsSLSSELLAS Life Sciences Group$2.14-0.9%$1.80$0.77▼$2.29$267.67M2.623.14 million shs4.81 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%-2.83%-12.20%-2.19%-13.23%OGENOragenics0.00%-3.08%+4.13%-6.67%-87.52%PLXPPLx Pharma0.00%0.00%0.00%0.00%0.00%QLGNQualigen Therapeutics0.00%-12.50%+28.17%+20.93%-54.81%SLSSELLAS Life Sciences Group0.00%+12.04%+32.92%+20.90%+71.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 1.00SellN/AN/AOGENOragenics 0.00N/AN/AN/APLXPPLx Pharma 0.00N/AN/AN/AQLGNQualigen Therapeutics 1.00SellN/AN/ASLSSELLAS Life Sciences Group 2.00Hold$7.00227.10% UpsideCurrent Analyst Ratings BreakdownLatest OGEN, QLGN, SLS, PLXP, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025EVOKEvoke PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025QLGNQualigen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SLSSELLAS Life Sciences GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025EVOKEvoke PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025QLGNQualigen TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SLSSELLAS Life Sciences GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$12.79M0.54N/AN/A$4.74 per share0.94OGENOragenics$40K130.10N/AN/A($0.51) per share-2.47PLXPPLx Pharma$4.54M0.00N/AN/A$1.30 per share0.00QLGNQualigen Therapeutics$4.98M1.24N/AN/A($4.12) per share-0.88SLSSELLAS Life Sciences Group$1M267.67N/AN/A$0.13 per share16.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.56N/A∞N/A-42.07%-99.48%-33.58%11/6/2025 (Estimated)OGENOragenics-$10.57M-$21.42N/A∞N/AN/A-3,614.27%-324.80%N/APLXPPLx Pharma-$46.13M-$1.85N/AN/AN/A-606.91%-291.11%-119.43%N/AQLGNQualigen Therapeutics-$6.26MN/A0.00∞N/AN/AN/A-202.16%11/13/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.32N/AN/AN/AN/A-132.51%-92.79%11/12/2025 (Estimated)Latest OGEN, QLGN, SLS, PLXP, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025SLSSELLAS Life Sciences Group-$0.0767N/AN/AN/AN/AN/A8/14/2025Q2 2025EVOKEvoke Pharma-$0.30-$0.62-$0.32-$0.62$3.80 million$3.75 million8/14/2025Q2 2025QLGNQualigen TherapeuticsN/A-$1.00N/A-$1.00N/AN/A8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767-$0.07+$0.0067-$0.07N/AN/A7/21/2025Q1 2025QLGNQualigen TherapeuticsN/A-$1.82N/A-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/APLXPPLx PharmaN/AN/AN/AN/AN/AQLGNQualigen TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.371.32OGENOragenicsN/A0.500.50PLXPPLx PharmaN/A4.794.28QLGNQualigen TherapeuticsN/A0.710.71SLSSELLAS Life Sciences GroupN/A4.914.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AOGENOragenics18.71%PLXPPLx Pharma21.19%QLGNQualigen Therapeutics3.18%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%OGENOragenics4.90%PLXPPLx Pharma8.95%QLGNQualigen Therapeutics1.80%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.56 million1.52 millionNot OptionableOGENOragenics54.13 million3.93 millionN/APLXPPLx Pharma1629.14 million26.53 millionNot OptionableQLGNQualigen Therapeutics501.70 million1.66 millionNot OptionableSLSSELLAS Life Sciences Group10125.08 million123.33 millionNot OptionableOGEN, QLGN, SLS, PLXP, and EVOK HeadlinesRecent News About These CompaniesBlackRock just bought this stock with full voting controlOctober 18 at 7:28 AM | finbold.comFTraders Purchase High Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)October 16 at 2:11 AM | americanbankingnews.comSELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)October 14, 2025 | marketbeat.comSellas Life Sciences to present in vivo preclinical data on SLS009October 13, 2025 | msn.comSELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer TreatmentOctober 13, 2025 | msn.comSELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European ...October 13, 2025 | markets.businessinsider.comSELLAS Life Sciences Presents Preclinical Efficacy Data for CDK9 Inhibitor SLS009 in T-Cell Prolymphocytic Leukemia at ESMO Congress 2025October 13, 2025 | quiverquant.comQSellas Life Sciences files to sell 19.69M shares of common stock for holdersOctober 10, 2025 | msn.comWeiss Ratings Reiterates Sell (D-) Rating for SELLAS Life Sciences Group (NASDAQ:SLS)October 9, 2025 | marketbeat.comShort Interest in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Drops By 28.8%October 8, 2025 | americanbankingnews.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short InterestOctober 7, 2025 | marketbeat.comSELLAS Extends Times Square Sublease AgreementOctober 3, 2025 | tipranks.comSELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL ...September 30, 2025 | markets.businessinsider.comSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current ...September 13, 2025 | bakersfield.comBSellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing WarrantsSeptember 12, 2025 | msn.comSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross ProceedsSeptember 11, 2025 | markets.businessinsider.comSELLAS Life Sciences Group, Inc. Announces Immediate Exercise of Warrants, Raising Approximately $23.6 MillionSeptember 11, 2025 | quiverquant.comQSellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026August 19, 2025 | seekingalpha.comSellas Life Sciences Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comSellas Life Sciences reports Q2 EPS (7c), consensus (8c)August 12, 2025 | msn.comSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOGEN, QLGN, SLS, PLXP, and EVOK Company DescriptionsEvoke Pharma NASDAQ:EVOK$4.46 -0.06 (-1.33%) Closing price 10/17/2025 03:59 PM EasternExtended Trading$4.53 +0.07 (+1.46%) As of 10/17/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Oragenics NYSEAMERICAN:OGEN$1.26 -0.04 (-3.08%) Closing price 10/17/2025 04:10 PM EasternExtended Trading$1.25 -0.01 (-0.48%) As of 10/17/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.PLx Pharma NASDAQ:PLXPPLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.Qualigen Therapeutics NASDAQ:QLGN$3.64 -0.09 (-2.41%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.60 -0.04 (-1.10%) As of 10/17/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.SELLAS Life Sciences Group NASDAQ:SLS$2.14 -0.02 (-0.93%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.94 +0.80 (+37.43%) As of 10/17/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
